Long-term Efficacy and Safety Following Switch Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: 5-Year Data from SELECT-COMPARE

CONCLUSION: Switching to a different MoA may provide long-term benefit to patients with RA not achieving treatment goals with their initial therapy, with acceptable safety profiles.TRIAL REGISTRATION: NCT02629159.PMID:38498140 | DOI:10.1007/s40744-024-00658-1

Source: Herpes - March 18, 2024 Category: Infectious Diseases Authors: Roy Fleischmann Ricardo Blanco Filip Van den Bosch Louis Bessette Yanna Song Sara K Penn Erin McDearmon-Blondell Nasser Khan Kelly Chan Eduardo Mysler Source Type: research